Skip to content

Study · Randomized controlled trial · n = 27 · 2003

4 results

Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.

Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr

The Journal of clinical endocrinology and metabolism1 Sept 2003Cited by 190 (Europe PMC)

PMID12970289 (opens in a new tab)DOI10.1210/jc.2002-021736 (opens in a new tab)PepBankPUB-12970289
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, serum calcium remained similar with PTH and calcitriol plus calcium, within or just below normal.

    In plain wordsIn patients with hypoparathyroidism, blood calcium stayed similar with PTH and calcitriol plus calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSerum calcium
    Study

    n = 27

    Comparator
    Calcitriol and calcium
    Analysis
    Primary
    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    Throughout the 3-yr study period, serum calcium levels were similar in both treatment groups within or just below the normal range.
    2 context sentences
    Summary · context
    The primary end points were calcium levels in serum and urine.
    Summary · context
    In this randomized, parallel group, open-label trial, we compared synthetic human PTH-(1-34) (PTH) with conventional therapy, calcitriol and calcium, over a 3-yr period. Twenty-seven patients with confirmed hypoparathyroidism, aged 18-70 yr, were randomized to either twice daily sc PTH or oral calcitriol and calcium.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, urinary calcium was normal during PTH treatment but remained above normal with calcitriol.

    In plain wordsIn patients with hypoparathyroidism, urine calcium was normal with PTH but above normal with calcitriol.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseUrinary calcium excretion
    Study

    n = 27

    Comparator
    Calcitriol and calcium
    Analysis
    Primary
    Outcome group
    Bone and joint · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneous · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    Mean urinary calcium excretion was within the normal range from 1-3 yr in PTH-treated patients, but remained above normal in the calcitriol group.
    2 context sentences
    Summary · context
    The primary end points were calcium levels in serum and urine.
    Summary · context
    In this randomized, parallel group, open-label trial, we compared synthetic human PTH-(1-34) (PTH) with conventional therapy, calcitriol and calcium, over a 3-yr period. Twenty-seven patients with confirmed hypoparathyroidism, aged 18-70 yr, were randomized to either twice daily sc PTH or oral calcitriol and calcium.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, bone mineral density did not differ significantly between PTH and calcitriol plus calcium.

    In plain wordsIn patients with hypoparathyroidism, bone density did not differ significantly between PTH and calcitriol plus calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone mineral density
    Study

    n = 27

    Comparator
    Calcitriol and calcium
    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral content and bone mineral density showed no significant between-group differences over the 3-yr study period.
    2 context sentences
    Summary · context
    Secondary end points were creatinine clearance, markers of bone turnover, and bone mineral density.
    Summary · context
    In this randomized, parallel group, open-label trial, we compared synthetic human PTH-(1-34) (PTH) with conventional therapy, calcitriol and calcium, over a 3-yr period. Twenty-seven patients with confirmed hypoparathyroidism, aged 18-70 yr, were randomized to either twice daily sc PTH or oral calcitriol and calcium.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, bone mineral content did not differ significantly between PTH and calcitriol plus calcium.

    In plain wordsIn patients with hypoparathyroidism, bone mineral content did not differ significantly between PTH and calcitriol plus calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone mineral content
    Study

    n = 27

    Comparator
    Calcitriol and calcium
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral content and bone mineral density showed no significant between-group differences over the 3-yr study period.
    1 context sentence
    Summary · context
    In this randomized, parallel group, open-label trial, we compared synthetic human PTH-(1-34) (PTH) with conventional therapy, calcitriol and calcium, over a 3-yr period. Twenty-seven patients with confirmed hypoparathyroidism, aged 18-70 yr, were randomized to either twice daily sc PTH or oral calcitriol and calcium.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00001304

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)n = 27Oct 1991 to Apr 2014

Hypoparathyroidism

Trial pageClinicalTrials.govUpdated 15 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.